Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Morria Biopharmaceuticals has obtained regulatory approval from the South African Medicines Control Council to initiate a Phase II study of MRX-4 in 105 patients suffering from allergic rhinitis.
Subscribe to our email newsletter
The two-arm, randomized, multi-dose, double-blind, placebo-controlled study includes a steroid comparator arm. The study will evaluate the safety, tolerability, and preliminary efficacy of intranasal MRX-4 in allergic rhinitis (AR) patients outside of allergy season as compared with both placebo and an intranasal steroid.
An experimental multi-functional anti-inflammatory drug, MRX-4 is a non-steroidal potential treatment for AR that was shown to be safe and well tolerated in a Phase I equivalent trial completed in Israel earlier this year.
Yuval Cohen, president of Morria, said: “This study will provide valuable data regarding its potential in allergic rhinitis, including efficacy, tolerability and pharmacokinetic data.”